Flag of the European Union EU Clinical Trials Register Help

Clinical trials for B Cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,078 result(s) found for: B Cell. Displaying page 1 of 204.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-007799-40 Sponsor Protocol Number: 2021/07 Start Date*: 2008-01-28
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Evaluation of intralesional administration of rituximab for treatment of orbital lymphoma
    Medical condition: orbital lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003899 B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002865-39 Sponsor Protocol Number: TCD12333 Start Date*: 2012-10-03
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: An open label, multicenter phase II study of intravenous SAR3419, an anti-CD19 antibody-maytansine conjugate, in combination with rituximab in patients with relapsed or refractory Diffuse Large B C...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001673-14 Sponsor Protocol Number: CCTL019A2205B Start Date*: 2015-10-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
    Medical condition: All patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FI (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003511-20 Sponsor Protocol Number: 201700599 Start Date*: 2019-01-30
    Sponsor Name:HOVON Foundation
    Full Title: Molecular imaging of zirconium-89-labeled atezolizumab in high-risk diffuse large B-cell lymphoma prior to atezolizumab treatment
    Medical condition: Diffuse large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003657-87 Sponsor Protocol Number: BCNHL Start Date*: 2007-09-14
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Reduced intensity conditioning with high-dose rituximab followed by allogeneic transplantation of hematopoietic cells for the treatment of relapsed/refractory B-cell non Hodgkin’s lymphomas
    Medical condition: B-cell non-Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000327-18 Sponsor Protocol Number: CLL 2007 FMP Start Date*: 2007-07-06
    Sponsor Name:GOELAMS
    Full Title: Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previo...
    Medical condition: Rituximab and Campath are two antibodies directed against CD20 and CD52 antigen, respectively. The highest response rate in the B-CLL treatment has been obtained by the association of Fludarabine,...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000860-28 Sponsor Protocol Number: 02CLLIII Start Date*: 2004-12-02
    Sponsor Name:ribosepharm GmbH
    Full Title: PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF BENDAMUSTINE HYDROCHLORIDE VERSUS CHLORAMBUCIL IN TREATMENT-NAÏVE PATIENTS WITH (BINET STAGE B/C) B-CLL REQUIRING THERAPY
    Medical condition: Hematopoietic insufficiency with non-hemolysis-induced Hb <10 g/dL Thrombocytopenia <100x109/L (equivalent to Binet stage C) B symptoms Rapidly progressive disease (such as rapid lymphoma growth, r...
    Disease: Version SOC Term Classification Code Term Level
    7 10008956 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004097-26 Sponsor Protocol Number: PCI-32765FLR2002 Start Date*: 2013-02-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003079-32 Sponsor Protocol Number: CC-5013-CLL-008 Start Date*: 2009-06-19
    Sponsor Name:Celgene Corporation
    Full Title: ESTUDIO FASE 3, MULTICÉNTRICO, ALEATORIZADO, ABIERTO Y DE GRUPOS PARALELOS PARA VALORAR LA EFICACIA Y SEGURIDAD DE LENALIDOMIDA (REVLIMID®) FRENTE A CLORAMBUCILO COMO TERAPIA DE PRIMERA LÍNEA EN PA...
    Medical condition: TERAPIA DE PRIMERA LÍNEA EN PACIENTES ANCIANOS CON LEUCEMIA LINFOCÍTICA CRÓNICA DE CÉLULAS B NO TRATADOS PREVIAMENTE (FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRON...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-002987-24 Sponsor Protocol Number: 152CL201 Start Date*: 2007-06-25
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclopho...
    Medical condition: Relapsed Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) SK (Completed) PT (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001433-17 Sponsor Protocol Number: Hx-CD20-405 Start Date*: 2006-06-30
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in...
    Medical condition: Non-Hodgkin Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003899 B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) DK (Prematurely Ended) DE (Completed) ES (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006999-38 Sponsor Protocol Number: IIL-SNCL1 Start Date*: 2008-01-07
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) SUPPORTED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC B-CELL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNO...
    Medical condition: PATIENTS WITH SYSTEMIC B-CELL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OR RELAPSE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003899 B-cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024004-98 Sponsor Protocol Number: DSHNHL2010-1 Start Date*: 2012-04-25
    Sponsor Name:University Medicine Göttingen Dept. Hematology and Oncology
    Full Title: Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients("slow go") with Aggressive CD-20-positive B-cell Lymphoma Short tiltle: BRENDA
    Medical condition: Very elderly or elderly medically non fit patients with aggressive CD20 positive B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001246-14 Sponsor Protocol Number: 701 Start Date*: 2011-06-08
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
    Full Title: Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell trans...
    Medical condition: Adult agressive B-cell non-Hodgkin lymphoma patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    14.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005378-73 Sponsor Protocol Number: TBF2012 Start Date*: 2013-01-29
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: Allogeneic Transplantation after a Conditioning with Thiotepa, Busulfan and Fludarabin for the treatment of refractory/early relapsed aggressive B-cell non Hodgkin lymphomas: a Phase II Multi-Cente...
    Medical condition: Refractory/early relapsed aggressive B-cell non Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000937-15 Sponsor Protocol Number: HO161 Start Date*: 2022-08-25
    Sponsor Name:UMCG
    Full Title: A phase II non-inferiority design study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma
    Medical condition: B-Cell Non Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017449-72 Sponsor Protocol Number: 1840 Start Date*: 2010-01-14
    Sponsor Name:FRED HUTCHINSON CANCER RESEARCH CENTER UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE CHILDREN
    Full Title: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukem...
    Medical condition: Patients with Advanced Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003828-38 Sponsor Protocol Number: ZEVALIN one shot LNH >60aa Start Date*: 2008-09-01
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
    Full Title: Yttrium Y90Ibritumomab Tiutexan (Zevalin)as a consolidation treatment for patients with high grade non-Hodgkin's lymphoma aged >60 years.
    Medical condition: High grade B cell non-Hodgkin lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003796-20 Sponsor Protocol Number: HOVON 77 Start Date*: 2007-01-03
    Sponsor Name:HOVON Foundation
    Full Title: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission f...
    Medical condition: patients with diffuse Large B-Cell lymphoma, CD20-positive
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-005777-30 Sponsor Protocol Number: 26866138-LYM-3001 Start Date*: 2006-03-31
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non Hodgkin's Lymphoma
    Medical condition: Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025320
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SK (Completed) ES (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 07:50:56 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA